192 related articles for article (PubMed ID: 16835310)
21. Febuxostat versus allopurinol for gout.
Lustberg ME
N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16598054
[No Abstract] [Full Text] [Related]
22. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
[TBL] [Abstract][Full Text] [Related]
23. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
[TBL] [Abstract][Full Text] [Related]
24. Allopurinol and kidney function: An update.
Stamp LK; Chapman PT; Palmer SC
Joint Bone Spine; 2016 Jan; 83(1):19-24. PubMed ID: 26453097
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of hyperuricemia and gout].
Gröbner W; Walter-Sack I
Med Monatsschr Pharm; 2005 May; 28(5):159-64; quiz 165-6. PubMed ID: 15912988
[No Abstract] [Full Text] [Related]
26. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
White WB; Chohan S; Dabholkar A; Hunt B; Jackson R
Am Heart J; 2012 Jul; 164(1):14-20. PubMed ID: 22795277
[TBL] [Abstract][Full Text] [Related]
27. Gout: its causes, symptoms and treatment.
Hill J
Nurs Times; 1999 Nov 24-Dec 1; 95(47):48-50. PubMed ID: 11096905
[No Abstract] [Full Text] [Related]
28. Allopurinol-induced drug reaction with eosinophilia and systemic symptoms syndrome with recurrence.
Yang DC; Chang CM
J Am Geriatr Soc; 2010 Oct; 58(10):2043-4. PubMed ID: 20929487
[No Abstract] [Full Text] [Related]
29. Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system.
Mikuls TR; Curtis JR; Allison JJ; Hicks RW; Saag KG
J Rheumatol; 2006 Mar; 33(3):562-6. PubMed ID: 16482645
[TBL] [Abstract][Full Text] [Related]
30. [Febuxostat versus allopurinol for hyperuricemia].
Ziegler R
Med Monatsschr Pharm; 2006 Oct; 29(10):384. PubMed ID: 17058902
[No Abstract] [Full Text] [Related]
31. [Fatal outcome in allopurinol hypersensitivity syndrome].
Kluger E
Ugeskr Laeger; 1998 Feb; 160(8):1179-80. PubMed ID: 9492630
[TBL] [Abstract][Full Text] [Related]
32. Factors associated with recurrent hospital admissions for gout: a case-control study.
Hutton I; Gamble G; Gow P; Dalbeth N
J Clin Rheumatol; 2009 Sep; 15(6):271-4. PubMed ID: 19734730
[TBL] [Abstract][Full Text] [Related]
33. Treatment failure gout: failure to treat?
Perry ME; Madhok R
Rheumatology (Oxford); 2010 Dec; 49(12):2233-4. PubMed ID: 20463191
[No Abstract] [Full Text] [Related]
34. Successful desensitisation of allopurinol-induced erythema multiforme.
Fonseka MM; Sathischandra H; Jayamanne SF; de Silva HJ
Ceylon Med J; 1999 Dec; 44(4):190-1. PubMed ID: 10895280
[No Abstract] [Full Text] [Related]
35. Gout management: let's get it right this time.
Sundy JS
Arthritis Rheum; 2008 Nov; 59(11):1535-7. PubMed ID: 18975368
[No Abstract] [Full Text] [Related]
36. Case 9: initiation of urate-lowering therapy for advanced gout complicated by chronic renal insufficiency.
Edwards NL
Am J Med; 2006 Nov; 119(11 Suppl 1):S29-31. PubMed ID: 17059911
[No Abstract] [Full Text] [Related]
37. Prevention of colchicine toxicity in patients with gout.
Dalbeth N; Gow P
N Z Med J; 2007 Apr; 120(1252):U2503. PubMed ID: 17460750
[No Abstract] [Full Text] [Related]
38. Allopurinol induced generalized eosinophilic pustular folliculitis.
Ooi CG; Walker P; Sidhu SK; Gordon LA; Marshman G
Australas J Dermatol; 2006 Nov; 47(4):270-3. PubMed ID: 17034470
[TBL] [Abstract][Full Text] [Related]
39. Inappropriate prescription of allopurinol in a teaching hospital.
Athisakul S; Wangkaew S; Louthrenoo W
J Med Assoc Thai; 2007 May; 90(5):889-94. PubMed ID: 17596042
[TBL] [Abstract][Full Text] [Related]
40. Allopurinol and Loss of Consciousness in a 78-old Year Man Suffering from Gout.
Arian M; AkbariRad M; Moghaddam AB; Firoozi A; Jami M
Infect Disord Drug Targets; 2020; 20(2):253-256. PubMed ID: 30686265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
